Skip to content

Study · Animal study (in vivo) · mouse · 2021

5 results

LR12 Promotes Liver Repair by Improving the Resolution of Inflammation and Liver Regeneration in Mice with Thioacetamide- (TAA-) Induced Acute Liver Failure.

Wang Y, Xie X, Liu H, Liu H, Jiang H, Jiang H

Mediators of inflammation28 May 2021Cited by 12 (Europe PMC)

PMID34135689 (opens in a new tab)PMCIDPMC8179768 (opens in a new tab)DOI10.1155/2021/2327721 (opens in a new tab)PepBankPUB-34135689
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

BackgroundTriggering receptor expressed on myeloid cells-1 (TREM-1) controls the mobilization of inflammatory cells in response to injury and consequently enhances liver damage. LR12 is a TREM-1 inhibitory peptide. However, the role of LR12 in acute liver failure (ALF) has remained elusive. This study was aimed at indicating whether LR12 could promote liver repair in mice with thioacetamide- (TAA-) induced ALF.MethodsBALB/c mice were intraperitoneally injected with TAA, followed by intravenous injection of LR12. Damage and regeneration of the liver were assessed. LO2 cells and macrophages were used to assess the therapeutic effects of LR12.ResultsMice treated with TAA for 24 h developed ALF, while liver inflammation was alleviated after LR12 treatment. Moreover, LR12 promoted hepatocyte regeneration in mice with TAA-induced ALF. In vitro, the supernatant from TAA+LR12-treated macrophages promoted the proliferation of LO2 cells. Cytokine protein microarray analysis suggested that LR12 promoted the secretion of C-C chemokine ligand 20 (CCL20) from macrophages. Besides, neutralization of CCL20 blocked the effects of LR12, thus inhibited the proliferation of LO2 cells in vitro, aggregated the liver inflammation, and restrained hepatocyte regeneration in ALF mice in vivo. Furthermore, we also found that LR12 activated the p38 mitogen-activated protein kinase (MAPK) pathway in hepatocytes through promoting the secretion of CCL20 from macrophages.ConclusionsLR12 could improve the resolution of inflammation and liver regeneration in mice with TAA-induced ALF by promoting the secretion of CCL20 from macrophages and activating the p38 MAPK pathway. Therefore, LR12 could be an attractive therapeutic target for the treatment of ALF.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TAA-induced acute liver failure, LR12 alleviated liver inflammation.

    In plain wordsIn mice with TAA-induced acute liver failure, LR12 reduced liver inflammation.

    Peptide
    Nangibotide
    Outcome
    DecreaseLiver inflammation
    Study

    mousen: not reported in source

    TAA-induced acute liver failure in BALB/c mice
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    Mice treated with TAA for 24 h developed ALF, while liver inflammation was alleviated after LR12 treatment.
    1 context sentence
    Summary · context
    BALB/c mice were intraperitoneally injected with TAA, followed by intravenous injection of LR12.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TAA-induced acute liver failure, LR12 promoted hepatocyte regeneration.

    In plain wordsIn mice with TAA-induced acute liver failure, LR12 increased liver cell regeneration.

    Peptide
    Nangibotide
    Outcome
    IncreaseHepatocyte regeneration
    Study

    mousen: not reported in source

    TAA-induced acute liver failure in BALB/c mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, LR12 promoted hepatocyte regeneration in mice with TAA-induced ALF.
    1 context sentence
    Summary · context
    BALB/c mice were intraperitoneally injected with TAA, followed by intravenous injection of LR12.
  3. 03LabIn vitro (cells)Mechanism

    In macrophages, cytokine microarray analysis suggested that LR12 promoted CCL20 secretion.

    In plain wordsIn cells, analysis suggested that LR12 increased macrophage secretion of CCL20.

    Peptide
    Nangibotide
    Outcome
    IncreaseCCL20 secretion
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cytokine protein microarray analysis suggested that LR12 promoted the secretion of C-C chemokine ligand 20 (CCL20) from macrophages.
  4. 04LabIn vitro (cells)Mechanism

    In hepatocytes, LR12 activated p38 MAPK signaling through increased CCL20 secretion from macrophages.

    In plain wordsIn lab tests, LR12 activated hepatocyte p38 MAPK signaling through increased CCL20 secretion from macrophages.

    Peptide
    Nangibotide
    Outcome
    Increasep38 MAPK activation
    Study

    n: not reported in source

    Hepatocytes and macrophages
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, we also found that LR12 activated the p38 mitogen-activated protein kinase (MAPK) pathway in hepatocytes through promoting the secretion of CCL20 from macrophages.

Studies that did not test the peptide alone1

In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Nangibotide.

  1. 05LabNot a test of Nangibotide aloneIn vitro (cells)Mechanism

    In vitro, supernatant from TAA+LR12-treated macrophages promoted LO2 cell proliferation.

    In plain wordsIn cells, fluid from macrophages treated with TAA and LR12 increased LO2 liver cell proliferation.

    Peptide
    Nangibotide
    Outcome
    IncreaseLO2 cell proliferation with conditioned medium
    Study

    n: not reported in source

    LO2 cells exposed to macrophage supernatant
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    In vitro, the supernatant from TAA+LR12-treated macrophages promoted the proliferation of LO2 cells.

    In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nangibotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.